Blog
RSS FeedPosted by Michael Wonder on 24 Dec 2025
Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars
24 December 2025 - More than 7,000 people in England will now be able to access to a life-extending treatment for ...
Posted by Michael Wonder on 19 Sep 2025
Biocon Biologics' Yesafili (aflibercept) now publicly funded in Ontario, Canada for the advanced treatment of patients with retinal diseases
18 September 2025 - -- Biocon Biologics is pleased to announce that Yesafili (aflibercept), a biosimilar to Eylea (aflibercept) injection, ...
Posted by Michael Wonder on 10 Dec 2024
PHARMAC seeks feedback to fund medicines for liver and ovarian cancer
9 December 2024 - PHARMAC is consulting on a proposal to fund bevacizumab (branded as Vegzelma) as a cancer medicine ...
Posted by Michael Wonder on 24 Oct 2024
Driving down the cost of biologics: lessons from a nationalised health care system
18 October 2024 - Few treatments have revolutionised care for people with chronic inflammatory disorders more than biologic and small molecule ...
Posted by Michael Wonder on 21 Dec 2022
Ontario expanding safe use of biosimilars
20 December 2022 - Transitioning to biosimilars will allow province to invest in and improve access to medicines. ...
Posted by Michael Wonder on 24 Oct 2022
Saskatchewan becomes sixth Canadian province to implement a biosimilar switching policy
21 October 2022 - Saskatchewan joined five provinces and one territory in implementing a biosimilar switching policy, allowing for reference ...
Posted by Michael Wonder on 12 Oct 2022
Medical industry advocates urge Ontario to offer cheaper versions of prescription medications
11 October 2022 - Medical industry advocates are urging the Ontario government to offer cheaper versions of certain prescription medications ...
Posted by Michael Wonder on 03 Jul 2022
NHS saves 1.2 billion pounds on medicines over three years
1 July 2022 - The NHS has saved taxpayers £1.2 billion in just three years, while securing cutting-edge treatments for ...
Posted by Michael Wonder on 31 May 2022
Schedule of Pharmaceutical Benefits - 1 June 2022
1 June 2022 - The June 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 May 2022
2022 Biosimilar Awareness Week: 30 May – 3 June
30 May 2022 - Marking a new dawn in medicine choice and affordability. ...
Posted by Michael Wonder on 09 Feb 2022
Nova Scotia becomes fifth Canadian province to implement a biosimilar switching program
5 February 2022 - The province is the latest jurisdiction to adopt a program that will require patients to switch ...
Posted by Michael Wonder on 07 Dec 2021
Biosimilar follitropin alfa on the PBS - information for health care professionals and patients
7 December 2021 - A biosimilar brand of follitropin alfa (Ovaleap) was listed on the PBS on 1 December 2021. ...
Posted by Michael Wonder on 16 Nov 2021
PHARMAC widens access to adalimumab through transition to biosimilar
17 November 2021 - Pharmac’s chief medical officer Dr David Hughes has today announced the decision to fund a biosimilar adalimumab ...
Posted by Michael Wonder on 11 Nov 2021
Patient access to affordable cancer treatment increases with the launch of new biosimilar in Canada
9 November 2021 - Apobiologix today launched its first oncology therapeutic treatment Bambevi (bevacizumab), which is used in combination with ...
Posted by Michael Wonder on 19 Oct 2021
Strategies for generic/biosimilar market entry in Australia
19 October 2021 - After surviving the Great Patent Cliff of 2011–2016, the pharma/biopharma industry finds itself in the Second Great ...